CA2971732A1 - Antibodies to tigit - Google Patents

Antibodies to tigit Download PDF

Info

Publication number
CA2971732A1
CA2971732A1 CA2971732A CA2971732A CA2971732A1 CA 2971732 A1 CA2971732 A1 CA 2971732A1 CA 2971732 A CA2971732 A CA 2971732A CA 2971732 A CA2971732 A CA 2971732A CA 2971732 A1 CA2971732 A1 CA 2971732A1
Authority
CA
Canada
Prior art keywords
antibody
tigit
antibodies
cancer
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2971732A
Other languages
English (en)
French (fr)
Other versions
CA2971732C (en
Inventor
Mark F. Maurer
Tseng-Hui Timothy Chen
Brigitte Devaux
Mohan Srinivasan
Susan H. Julien
Paul O. Sheppard
Daniel F. Ardourel
Indrani CHAKRABORTY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CA2971732A1 publication Critical patent/CA2971732A1/en
Application granted granted Critical
Publication of CA2971732C publication Critical patent/CA2971732C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2971732A 2014-12-23 2015-12-22 Antibodies to tigit Active CA2971732C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462096267P 2014-12-23 2014-12-23
US62/096,267 2014-12-23
PCT/US2015/067332 WO2016106302A1 (en) 2014-12-23 2015-12-22 Antibodies to tigit

Publications (2)

Publication Number Publication Date
CA2971732A1 true CA2971732A1 (en) 2016-06-30
CA2971732C CA2971732C (en) 2025-09-16

Family

ID=

Also Published As

Publication number Publication date
KR20170099966A (ko) 2017-09-01
IL253013B (en) 2021-08-31
JP2018035138A (ja) 2018-03-08
SG10202006538TA (en) 2020-08-28
PH12022550771A1 (en) 2023-02-27
IL285287B1 (en) 2023-03-01
US12060421B2 (en) 2024-08-13
JP2023139046A (ja) 2023-10-03
IL285287A (en) 2021-09-30
MX389267B (es) 2025-03-20
ZA201806307B (en) 2022-03-30
US20210324072A1 (en) 2021-10-21
KR102644115B1 (ko) 2024-03-05
CN110256558A (zh) 2019-09-20
US20160176963A1 (en) 2016-06-23
TWI708786B (zh) 2020-11-01
EP3237448A1 (en) 2017-11-01
EP4249066A3 (en) 2023-11-22
CL2017001660A1 (es) 2018-03-23
MX2021012074A (es) 2021-11-03
CN107207594A (zh) 2017-09-26
EA201791171A1 (ru) 2017-11-30
AU2015369683B2 (en) 2020-12-10
PH12017501166B1 (en) 2017-12-11
US20190112375A1 (en) 2019-04-18
IL285287B2 (en) 2023-07-01
CN110256558B (zh) 2023-07-04
AU2015369683A1 (en) 2017-08-10
AR103268A1 (es) 2017-04-26
BR112017013385A2 (pt) 2018-02-06
CN107207594B (zh) 2019-05-07
ZA201704981B (en) 2019-08-28
MY187045A (en) 2021-08-27
US11008390B2 (en) 2021-05-18
WO2016106302A9 (en) 2017-06-22
UY36471A (es) 2016-06-30
PE20171244A1 (es) 2017-08-24
SG11201705063VA (en) 2017-07-28
TN2017000267A1 (en) 2018-10-19
AU2021201231A1 (en) 2021-03-11
TW201629102A (zh) 2016-08-16
CN116731176A (zh) 2023-09-12
JP2021177759A (ja) 2021-11-18
PH12017501166A1 (en) 2017-12-11
AU2015369683C1 (en) 2024-06-20
JP2017520512A (ja) 2017-07-27
WO2016106302A1 (en) 2016-06-30
JP2025128184A (ja) 2025-09-02
CO2017006989A2 (es) 2018-01-05
JP6180663B2 (ja) 2017-08-16
EP4249066A2 (en) 2023-09-27
MA40662A1 (fr) 2020-06-30
MA40662B1 (fr) 2020-12-31
EA039219B1 (ru) 2021-12-20
JP2020062026A (ja) 2020-04-23
AU2021201231B2 (en) 2024-02-22
JP6633032B2 (ja) 2020-01-22
US10189902B2 (en) 2019-01-29
MX2017007744A (es) 2017-09-05
IL253013A0 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
AU2021201231B2 (en) Antibodies to tigit
AU2016285913B2 (en) Antibodies to CD40
AU2016285920A1 (en) Antibodies to CD40 with enhanced agonist activity
AU2015349878A1 (en) Antibodies against CD73 and uses thereof
CA3016534A1 (en) Antibodies to cd40 with enhanced agonist activity
WO2021231732A1 (en) Antibodies to garp
CA2971732C (en) Antibodies to tigit

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201215

EEER Examination request

Effective date: 20201215

EEER Examination request

Effective date: 20201215

EEER Examination request

Effective date: 20201215

EEER Examination request

Effective date: 20201215

EEER Examination request

Effective date: 20201215

EEER Examination request

Effective date: 20201215

EEER Examination request

Effective date: 20201215